Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Puengel, Tobias; Tacke, Frank

doi:10.1111/apt.16077

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were similar to those reported in a study using RWD in Germany that reported the prevalence of NAFLD/NASH as 4.7% (215 655 out of 4 580 434 patients in the database) 41 . It is possible that patients with an ICD‐10 diagnosis code for NAFLD/NASH represent those with more advanced cases than in the broader population, which would also explain the higher than expected prevalence of ACLD/cirrhosis noted in our study 42 …”

Section: Discussionsupporting

confidence: 92%

NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database

Brozat,

Ntanios,

Malhotra

et al. 2023

Liver International

Self Cite

View full text Add to dashboard Cite

Background & AimsNon‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are potential risk factors for severe pneumonia and other infections. Available data on the role of NAFLD/NASH in worsening outcomes for COVID‐19 are controversial and might be confounded by comorbidities.MethodsWe used the PINC AI™ Healthcare Data Special Release (PHD‐SR) to identify patients with COVID‐19 (ICD‐10) at approximately 900 hospitals in the United States. We performed exact matching (age, gender, and ethnicity) for patients with or without NAFLD/NASH, adjusting for demographics (admission type, region) and comorbidities (e.g., obesity, diabetes) through inverse probability of treatment weighting and then analysed hospitalisation‐related outcomes.ResultsAmong 513 623 patients with SARS‐CoV‐2 (COVID‐19), we identified 14 667 with NAFLD/NASH who could be matched to 14 667 controls. Mean age was 57.6 (±14.9) years, 50.8% were females and 43.7% were non‐Hispanic whites. After matching, baseline characteristics (e.g., age, ethnicity, and gender) and comorbidities (e.g., hypertension, obesity, diabetes, and cardiovascular disease) were well balanced (standard difference (SD) <.10), except for cirrhosis and malignancies. Patients with COVID‐19 and NAFLD/NASH had higher FIB‐4 scores, a significantly longer hospital length of stay (LOS) and intensive care LOS than controls (9.4 vs. 8.3 days, and 10.4 vs. 9.3, respectively), even after adjusting for cirrhosis and malignancies. Patients with COVID‐19 and NAFLD/NASH also had significantly higher risk of needing invasive mandatory ventilation (IMV) (odds ratio 1.0727; 95% CI 1.0095–1.1400). Other outcomes were similar in both groups.ConclusionsIn this large real‐world cohort of patients hospitalised for COVID‐19 in the United States, NAFLD/NASH were obesity‐independent risk factors for complicated disease courses.

show abstract

Section: Discussionsupporting

confidence: 92%

NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database

Brozat,

Ntanios,

Malhotra

et al. 2023

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Abstract: LINKED CONTENTThis article is linked to Canbay et al paper. To view this article, visit https://doi.org/10.1111/apt.16016

Cited by 1 publication

References 10 publications

NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database

NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database

Contact Info

Product

Resources

About